BC Week In Review | Dec 8, 2017
Clinical News

Sunovion gets FDA approval for Lonhala Magnair COPD treatment

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA approved Lonhala Magnair glycopyrrolate (SUN-101/eFlow) as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),...
BC Week In Review | Aug 16, 2017
Clinical News

FDA accepts Sunovion's SUN-101 resubmission for COPD

In June, the Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA accepted for review a resubmitted NDA for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with...
BC Week In Review | Jun 1, 2017
Clinical News

Sunovion receives CRL for COPD candidate SUN-101

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BC Extra | May 30, 2017
Clinical News

FDA issues CRL for Sunovion’s COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BC Extra | Oct 13, 2016
Company News

FDA reviewing Sunovion's COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA accepted an NDA for SUN-101 , a formulation of glycopyrrolate delivered via the eFlow nebulizer system as a long-term maintenance treatment for...
BC Extra | Apr 28, 2016
Clinical News

Sunovion's SUN-101 meets in COPD Phase IIIs

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said glycopyrrolate ( SUN-101 ) delivered via the eFlow nebulizer system met the primary endpoint in the Phase III GOLDEN-3 and GOLDEN-4 trials to treat...
BioCentury | Jan 7, 2013
Finance

Novo's public moves

With small cap public biotechs living in a challenging financial environment, Novo A/S 's Novo Ventures group sees an opportunity to put its money to work. The group thinks depressed valuations mark an attractive entry...
BC Week In Review | Sep 10, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary completed its acquisition of Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101 . Sunovion...
BC Week In Review | Sep 3, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary will acquire Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101 . Elevation is also...
BC Extra | Aug 31, 2012
Company News

Sunovion to acquire Elevation

The Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) will acquire Elevation Pharmaceuticals Inc. (San Diego, Calif.) for $100 million up front and up to $300 million in development and commercial...
Items per page:
1 - 10 of 21
BC Week In Review | Dec 8, 2017
Clinical News

Sunovion gets FDA approval for Lonhala Magnair COPD treatment

The Sunovion Pharmaceuticals Inc. subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA approved Lonhala Magnair glycopyrrolate (SUN-101/eFlow) as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),...
BC Week In Review | Aug 16, 2017
Clinical News

FDA accepts Sunovion's SUN-101 resubmission for COPD

In June, the Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA accepted for review a resubmitted NDA for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with...
BC Week In Review | Jun 1, 2017
Clinical News

Sunovion receives CRL for COPD candidate SUN-101

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BC Extra | May 30, 2017
Clinical News

FDA issues CRL for Sunovion’s COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA issued a complete response letter for SUN-101 as a long-term maintenance treatment for airflow obstruction in patients with chronic obstructive pulmonary...
BC Extra | Oct 13, 2016
Company News

FDA reviewing Sunovion's COPD therapy

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA accepted an NDA for SUN-101 , a formulation of glycopyrrolate delivered via the eFlow nebulizer system as a long-term maintenance treatment for...
BC Extra | Apr 28, 2016
Clinical News

Sunovion's SUN-101 meets in COPD Phase IIIs

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said glycopyrrolate ( SUN-101 ) delivered via the eFlow nebulizer system met the primary endpoint in the Phase III GOLDEN-3 and GOLDEN-4 trials to treat...
BioCentury | Jan 7, 2013
Finance

Novo's public moves

With small cap public biotechs living in a challenging financial environment, Novo A/S 's Novo Ventures group sees an opportunity to put its money to work. The group thinks depressed valuations mark an attractive entry...
BC Week In Review | Sep 10, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary completed its acquisition of Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101 . Sunovion...
BC Week In Review | Sep 3, 2012
Company News

Elevation Pharmaceuticals, Dainippon Sumitomo deal

Dainippon's Sunovion Pharmaceuticals Inc. subsidiary will acquire Elevation for $100 million up front and up to $300 million in development and commercial milestones related to chronic obstructive pulmonary disease (COPD) product EP-101 . Elevation is also...
BC Extra | Aug 31, 2012
Company News

Sunovion to acquire Elevation

The Sunovion Pharmaceuticals Inc. subsidiary of Dainippon Sumitomo Pharma Co. Ltd. (Tokyo:4506; Osaka:4506) will acquire Elevation Pharmaceuticals Inc. (San Diego, Calif.) for $100 million up front and up to $300 million in development and commercial...
Items per page:
1 - 10 of 21